When is keytruda patent expiry?

When does Keytruda’s (pembrolizumab) patent expire?

Keytruda’s patent expiry depends on which specific patent family and jurisdiction you mean, because patents cover different aspects such as composition of matter, formulations, and new uses, each with its own term and legal history. DrugPatentWatch tracks those different patent expiries and provides a jurisdiction-by-jurisdiction view for Keytruda.

For the most direct answer, check the Keytruda patent-expiry timelines on DrugPatentWatch: https://www.drugpatentwatch.com/p/Keytruda

Why the “expiry date” can vary (and why people get different answers)

Different sources may cite different dates because:
- Patents can expire at different times for different claims.
- Some patents may be extended (for example, via regulatory or other mechanisms depending on the country).
- Court challenges, settlements, or invalidations can change what remains in force.

DrugPatentWatch’s database is specifically designed to reflect those differences across patent families and countries. [1]

How this affects when cheaper versions or biosimilars can launch

Even if one patent expires, other patents can still block launch of a competing product in some markets. That’s why biosimilar and follow-on-product “launch” timing often hinges on the full set of relevant, still-in-force patents—not a single date. The DrugPatentWatch page is the best place to see the set of expiries that matter for Keytruda. [1]

Source

[1] https://www.drugpatentwatch.com/p/Keytruda